Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes

Monica J Engstrøm, Signe Opdahl, Lars J Vatten, Olav A Haugen & Anna M Bofin

Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway, and 1Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway

Date of submission 16 June 2014
Accepted for publication 27 September 2014
Published online Article Accepted 3 October 2014

Engstrøm MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM (2015) Histopathology 66: 409–419. DOI: 10.1111/his.12572

Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes

Aims: The aim of this study was to compare breast cancer specific survival (BCSS) for invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) and, further, to evaluate critically the prognostic value of histopathological grading of ILC and examine E-cadherin as a prognostic marker in ILC.

Methods and results: The study comprised 116 lobular and 611 ductal breast carcinomas occurring between 1961 and 2008. All cases had been classified previously according to histopathological type and grade, stained for oestrogen receptor (ER), progesterone receptor (PR), antigen Ki67 (Ki67), epithelial growth factor receptor (EGFR), cytokeratin 5 (CK5) and human epidermal growth factor receptor 2 (HER2) and classified into molecular subtypes. For the present study, immunohistochemical staining for E-cadherin was performed. The Kaplan–Meier method and Cox proportional hazards models were used in the analyses. Grade 2 tumours comprised 85.3% of the lobular tumours and 51.9% of the ductal tumours. BCSS in ILC grade 2 was comparable to that of IDC grade 3. E-cadherin-negative ILC had a poorer prognosis compared to E-cadherin positive ILC and to IDC regardless of E-cadherin status.

Conclusions: The implication of histopathological grading may differ in ILC compared to IDC. E-cadherin may be useful in prognostication in ILC and thereby influence the determination of treatment strategies for this group of women.

Keywords: breast cancer, breast cancer-specific survival, E-cadherin, histopathological grade, invasive lobular carcinoma, prognosis

Introduction

Invasive lobular carcinoma (ILC) is defined as an invasive carcinoma comprising non-cohesive cells dispersed individually in a single-file linear pattern in a fibrous stroma and accounts for 5–15% of breast cancers.1–3 A number of variants of ILC do not show the classical morphological pattern, but loss of cell-to-cell cohesion is a common feature.3

Histopathological grade is an important prognostic tool.4–6 The Nottingham grading system classifies patients into groups with different prognoses.7 However, in ILC the suitability of grading is uncertain.8,9 Glandular structures are absent, mitoses are infrequent and the nuclei uniform. Thus, most ILCs are grade 2 and the prognostic value of grading is unclear.

Breast cancer treatment guidelines are based on hormone receptor, human epidermal growth factor receptor 2 (HER2) and proliferation (Ki67) status, in

Address for correspondence: M J Engstrom, Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. e-mail: monica.j.engstrom@ntnu.no

© 2014 The Authors. Histopathology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
addition to histopathological grade, tumour size and lymph node status.\textsuperscript{10} Histopathological type is not always included as a parameter in treatment guidelines, although favourable types may influence the choice of treatment.

E-cadherin (E-cad) is a transmembrane protein involved in cell-to-cell adhesion, and its loss promotes invasion and metastasis.\textsuperscript{11} Loss of E-cad is common in ILC,\textsuperscript{11,12} and supports the diagnosis of ILC.\textsuperscript{13} Although it has been suggested that low levels of E-cad are associated with poorer prognosis,\textsuperscript{14–16} its potential as a prognostic marker in ILC has not been clarified.

The aims of this study were to compare breast cancer-specific survival (BCSS) in ILC with invasive ductal carcinoma (IDC) in a cohort of breast cancer patients with a long follow-up, to assess the prognostic value of histopathological grading of ILC and to examine the potential of E-cad as a prognostic marker in ILC.

\textbf{Material and methods}

\textbf{STUDY POPULATION}

Between 1956 and 1959, women from Nord Trøndelag County in Norway were invited by the Norwegian Cancer Registry to participate in a breast cancer survey. The population has been described previously.\textsuperscript{17,18} Briefly, 25,897 women, born between 1886 and 1928, were invited. From 1961 to 2008, 1,393 women developed breast cancer. Cases occurring prior to 1961 were excluded. A total of 945 tissue samples were available at the Department of Pathology and Medical Genetics, St Olav’s Hospital, Trondheim, Norway, and 867 were suitable for inclusion in tissue microarrays (TMA). After linkage with the Cause of Death Registry of Norway and the Norwegian Cancer Registry, survival data were generated. Only cases of IDC of no special type and ILC (727 cases) were included in the present study.

\textbf{SPECIMEN CHARACTERISTICS}

All cases were classified into histopathological type and grade and reclassified into molecular subtypes using surrogate markers for gene expression analyses (Figure 1).\textsuperscript{17} Histopathological typing and grading was performed independently on full-face sections by two experienced pathologists (O.A.H., A.M.B.).\textsuperscript{3,5,19} Three 1-mm tissue cores from the periphery of each tumour were selected and assembled in TMAs. Immunohistochemical (IHC) staining was performed for oestrogen receptor (ER), progesterone receptor (PR), antigen Ki67 (Ki67), HER2, cytokeratin 5 (CK5) and epithelial growth factor receptor 1 (EGFR). HER2 gene amplification status was estimated using chromogenic in-situ hybridization (CISH). For the present study, IHC staining was performed for E-cad.

\textbf{ASSAY METHODS}

Assay methods for all markers except E-cad have been described in detail previously.\textsuperscript{17} For the present study, IHC for detection of E-cad was performed according to the manufacturer’s guidelines (Dako, Glostrup, Denmark). The sections were mounted on Superfrost+ glass slides, dried at 37°C overnight and stored at −20°C. Before staining, the slides were heated to 60°C for 2 h and pretreated in a PT Link pretreatment module for tissue specimens (Dako) with buffer (high pH target retrieval solution K8004) at 97°C for 20 min. Monoclonal mouse antibody (clone NCH-38), 55.2 mg/l dilution 1:100, was applied. For visualization, the Dako REAL\textsuperscript{TM} EnVision\textsuperscript{TM} detection system was used with peroxidase/diaminobenzidine (DAB)+, rabbit/mouse, code K5007.

\textbf{SCORING AND REPORTING}

The REMARK reporting recommendations for tumour marker studies were followed.\textsuperscript{20} All IHC evaluations were performed independently by two researchers. ER and PR were positive if ≥1% of the tumour cells showed positive nuclear staining. For Ki67, ≥15% stained nuclei was classified as Ki67\textsuperscript{high} and <15% as Ki67\textsuperscript{low}. A staining index (SI) (intensity × proportion) was calculated for CK5 and EGFR; SI of 0–1 was considered to be negative and 2–9 was considered to be positive, as described previously. HER2 gene amplification was defined as gene to chromosome ratio ≥2. In cases where CISH failed, +3 IHC staining for HER2 was recorded as positive.\textsuperscript{17} In the
present study, only moderate or strong continuous membrane staining for E-cad in >50% of tumour cells were classified as positive. There were very few cases with aberrant staining (cytoplasmic staining or intermittent membranous staining), and these were classified as negative.

**Statistical Analyses**

Follow-up was from date of diagnosis until death or 31 December 2010. Kaplan–Meier methods were used to estimate BCSS for ILC grade 2 compared to IDC grades 1, 2 and 3, and for comparing survival of ILC and IDC grade 2, E-cad+ and E-cad− tumours. Grade 2 ILC and IDC were compared for each of the following biomarker categories separately: ER+, Ki67low and HER2−. Comparison was made between ILC and IDC grade 2 tumours with the favourable biomarker profile (ER+ and HER2− and Ki67low). BCSS for luminal A and luminal B (HER2−) subtypes were compared for ILC and IDC separately. The log-rank test was used to compare survival curves, \( P < 0.05 \) was considered statistically significant. Cox proportional hazards models were used to estimate relative risks of death from breast cancer adjusted for age (5-year intervals), stage at diagnosis (I, II, III, IV, unknown) and time-period of diagnosis. Hazard ratios (HR) for ILC compared to IDC were calculated with 95% confidence intervals (CI). The numbers of cases of ILC grades 1 and 3 were too low for reliable analyses of grade and BCSS in ILC. The number of cases with an unfavourable biomarker profile (ER−, HER2+ and Ki67high) was too small for separate analysis (\( n = 39 \)). Statistical analyses were performed using Stata version 12.1 (Stata Corp., College Station, TX, USA).

**Ethics**

Approval was granted by the Regional Committee for Medical and Health Sciences Research Ethics, including dispensation from the requirement of patient consent (REK, Midt-Norge, ref. no. 836/2009).

**Results**

**Description of the Population**

Of the 727 cases, 16% were ILC and 84% were IDC (Table 1). During follow-up, 297 (40.9%) died from breast cancer and 304 (41.8%) died of other causes. At the end of the period, 126 (17.3%) were still alive. Mean age at diagnosis was 71.3 years for IDC and 73.3 years for ILC. Table 2 shows the treatments given.

**Tumour Characteristics**

Histopathological grade, tumour size, lymph node status, stage and molecular subtypes are given in Table 1. Table 3 shows the results of IHC and CISH. The proportion of histopathological grade 2 tumours was higher in ILC (85.3%) compared to IDC (51.9%). In ILC 87.9% were ER+ and 6.0% were HER2+, compared to 83.6% ER+ and 16.9% HER2+ in IDC. A higher proportion of IDC (16.4%) than IDC (7.5%) were >5 cm. However, the proportions of tumours between 2 and 5 cm were similar (42.2 versus 45.5%).

**Grade, Type and Prognosis**

Figure 2 shows BCSS for ILC grade 2 compared to IDC grades 1, 2 and 3. ILC grade 2 had poorer BCSS compared to IDC grade 2 (\( P = 0.01 \), log-rank test).- There was no significant difference in BCSS between ILC grade 2 and IDC grade 3 (\( P = 0.48 \), log-rank test). Table 4 shows the risk of death from breast cancer according to type. ILC grade 2 was compared to IDC grades 1, 2 and 3 separately. HRs were similar for ILC grade 2 and IDC grade 3, whereas IDC grade 2 had a significantly better survival than ILC grade 2 (HR: 0.66, 95% CI: 0.46–0.94). Adjustment for age, stage and time of diagnosis did not influence the results.

**Prognostic Value of Type in ER+, HER2− and Ki67low Tumours**

Table 5 shows risk of death from breast cancer according to type among patients with grade 2 tumours and clinically favourable biomarker profiles. For each marker status (ER+, HER2−, Ki67low), respectively, there was a significantly higher risk of death from ILC compared to IDC. Similarly, risk of death from breast cancer for patients with grade 2 tumours expressing a complete favourable biomarker profile (ER+, HER2− and Ki67low) was higher for ILC than for IDC (HR: 2.16, 95% CI: 1.34–3.49). Analysis of all grades did not alter the results (data not shown).

**Prognostic Value of Molecular Subtypes**

The proportions of HER2+ and/or ER− ILC were low compared to IDC, as reflected in the distribution
Table 1. Summary of patient and tumour characteristics

| Patient and tumour characteristics | Ductal | Lobular | Total |
|-----------------------------------|--------|---------|-------|
| Number (%)                        | 611 (84.0) | 116 (16.0) | 727 (100.0) |
| Number of breast cancer deaths (%)| 246 (40.3) | 51 (44.0) | 297 (40.9) |
| Mean age at diagnosis (SD)        | 71.3 (10.7) | 73.3 (9.1) | 71.7 (10.5) |
| Median years of follow-up after diagnosis (IQR) | 7.2 (10.6) | 4.8 (7.9) | 6.8 (10.4) |
| Tumour grade (%)                  |        |         |       |
| 1                                 | 61 (10.0) | 9 (7.8) | 70 (9.6) |
| 2                                 | 317 (51.9) | 99 (85.3) | 416 (57.2) |
| 3                                 | 233 (38.1) | 8 (6.9) | 241 (33.2) |
| Tumour size (%)                   |        |         |       |
| ≤2 cm                             | 182 (29.8) | 20 (17.2) | 202 (27.8) |
| >2 cm, ≤5 cm                      | 221 (36.2) | 43 (37.1) | 264 (36.3) |
| >5 cm                             | 46 (7.5) | 19 (16.4) | 65 (8.9) |
| Uncertain                         | 162 (26.1) | 34 (29.3) | 196 (27.0) |
| Lymph node status                 |        |         |       |
| No metastasis                     | 234 (38.3) | 45 (38.8) | 279 (38.4) |
| Metastasis detected               | 236 (38.6) | 38 (32.8) | 274 (37.7) |
| Not examined for metastasis       | 141 (23.1) | 33 (28.4) | 174 (23.9) |
| Stage at diagnosis                |        |         |       |
| Stage I                           | 294 (48.1) | 52 (44.8) | 346 (47.6) |
| Stage II                          | 246 (40.3) | 49 (42.2) | 295 (40.6) |
| Stage III                         | 37 (6.1) | 11 (9.5) | 48 (6.6) |
| Stage IV                          | 29 (4.8) | 4 (3.5) | 33 (4.5) |
| Stage uncertain                   | 5 (0.8) | 0 | 5 (0.7) |
| Molecular subtypes (%)            |        |         |       |
| Luminal A                         | 290 (47.5) | 63 (54.3) | 353 (48.6) |
| Luminal B (HER2⁻)                 | 170 (27.8) | 33 (28.5) | 203 (27.9) |
| Luminal B (HER2⁺)                 | 54 (8.8) | 6 (5.2) | 60 (8.3) |
| HER2 type                         | 49 (8.0) | 1 (0.9) | 50 (6.9) |
| Five negative phenotype           | 13 (2.1) | 11 (9.5) | 24 (3.3) |
| Basal phenotype                   | 35 (5.7) | 2 (1.7) | 37 (5.1) |

SD, standard deviation; IQR, interquartile range; HER2, human epidermal growth factor receptor 2.

of molecular subtypes (Table 1). Among 353 luminal A cases, 290 (82.2%) were ductal and 63 (17.8%) were lobular. Figure 3 shows that luminal A ILC had a poorer prognosis than luminal A IDC (P = 0.02, log-rank test). Luminal B (HER2⁻) IDC had a slightly better prognosis than luminal A and luminal B (HER2⁻) ILC (P = 0.39, log-rank test). Table 6 shows that risk of death from grade 2
Table 2. Summary of breast cancer therapies for all cases

|                          | Invasive ductal carcinoma\n\( n = 611\) (%) | Invasive lobular carcinoma\n\( n = 116\) (%) | Total\n\( n = 727\) (%) |
|--------------------------|---------------------------------|---------------------------------|---------------------|
| Mastectomy               | 524 (85.8)                      | 94 (81.0)                       | 618 (85.0)          |
| Breast conserving therapy| 61 (10.0)                       | 12 (10.4)                       | 73 (10.0)           |
| Only biopsy, no surgical treatment | 26 (4.3)               | 10 (8.6)                        | 36 (5.0)            |
| Axillary surgery (clearance or sentinel node) | 461 (75.5)               | 81 (69.9)                       | 542 (74.6)          |
| Hormone therapy*         | 134 (26.2**)                    | 31 (30.4**)                     | 165 (26.9**)        |
| Trastuzumab              | 0                               | 0                               | 0                   |
| Chemotherapy             | Unknown                         | Unknown                         | Unknown             |
| Radiation                | Unknown                         | Unknown                         | Unknown             |

*Estimated according to guidelines at diagnosis; **% of the hormone receptor-positive cases.

Table 3. Results of immunohistochemical and in-situ hybridization markers

|         | Ductal \( n = 611\) | Lobular \( n = 116\) | Total \( n = 727\) |
|---------|----------------------|-----------------------|---------------------|
| ER+     | 511 (83.6)           | 102 (87.9)            | 613 (84.3)          |
| ER−     | 98 (16.0)            | 14 (12.1)             | 112 (15.4)          |
| PR+     | 364 (59.6)           | 58 (50.0)             | 422 (58.1)          |
| PR−     | 246 (40.3)           | 58 (50.0)             | 304 (41.8)          |
| HER2+   | 103 (16.9)           | 7 (6.0)               | 110 (15.1)          |
| HER2−   | 508 (83.1)           | 109 (94.0)            | 617 (84.9)          |
| Ki67\text{high}       | 280 (45.8)           | 39 (33.6)             | 319 (43.9)          |
| Ki67\text{low}        | 330 (54.0)           | 77 (66.4)             | 407 (56.0)          |
| Not possible to interpret | 1 (0.2)               | 0                     | 1 (0.1)             |
| CK5+    | 120 (19.6)           | 4 (3.5)               | 124 (17.1)          |
| CK5−    | 491 (80.4)           | 112 (96.6)            | 603 (82.9)          |
| EGFR+   | 41 (6.7)             | 3 (2.6)               | 44 (6.1)            |
| EGFR−   | 570 (93.3)           | 113 (97.4)            | 683 (93.9)          |
| E-cad+  | 523 (85.6)           | 27 (23.3)             | 550 (75.7)          |
| E-cad−  | 69 (11.3)            | 86 (74.1)             | 155 (21.3)          |
| Not possible to interpret | 19 (3.1)             | 3 (2.6)               | 22 (3.0)            |

EGFR, epithelial growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.

© 2014 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 66, 409–419.
breast cancer was higher for luminal A ILC, luminal B (HER2−) ILC and luminal B (HER2−) IDC compared to luminal A IDC. The difference between luminal A IDC and ILC was statistically significant. The numbers in the other subtypes were too low for analysis.

Table 3 shows that 23.3% of ILC were E-cad+. Figure 4 shows BCSS for grade 2 E-cad+ and E-cad− ILC and IDC. E-cad− ILC had poorer prognosis than E-cad+ ILC (P = 0.005, log-rank test). Figure 5 shows examples of E-cad IHC staining. Table 7 shows that risk of death from breast cancer for ILC E-cad− was nearly twofold (HR: 1.96, 95% CI: 1.32–2.89) compared to IDC E-cad+. There was no clear difference in prognosis between IDC E-cad+, IDC E-cad− and ILC E-cad+. Adjustment for age, stage and time-period did not influence the results.

Discussion

The main finding in this study of a cohort of breast cancer patients with long-term follow-up was a significantly poorer prognosis for grade 2 ILC compared to grade 2 IDC. The prognosis for grade 2 ILC was comparable to that of grade 3 IDC. A similar pattern was observed when the analyses were restricted to tumours with positive prognostic marker profiles (ER+, HER2− and Ki67low). Furthermore, E-cad expression appeared to be a favourable prognostic marker in ILC.

In the Nottingham grading system gland formation, nuclear atypia/pleomorphism and mitosis counts are considered. However, because the morphological features of ILC differ from IDC, grade may have a different prognostic significance. This is an important discussion, because histopathological grade is one of several factors determining adjuvant therapy, whereas type is disregarded.

In agreement with others, there were few ILCs of grade 1 (7.8%) and grade 3 (6.9%) in this study, and the low numbers preclude survival analyses. Histopathological grading has been shown to be of independent prognostic value in ILC. However, the implications of grading in ILC may differ from IDC and its value as a prognostic tool must be considered in this light, particularly when determining treatment strategies.

ER, HER2 and Ki67 are important prognostic and/or predictive markers. In this study, the proportion of ILCs with a favourable marker profile was higher than in IDC.
compared to IDC, implying a better prognosis for ILC. However, even when restricting analyses to cases with favourable marker profiles, a significantly poorer prognosis was found in ILC compared to IDC. HER2+ cases in ILC were few (Table 2), thus limiting its utility as a prognostic marker in ILC. Better prognostic markers for ILC are required.

In this study, E-cad+ grade 2 ILC was prognostically comparable to grade 2 IDC (both E-cad+ and E-cad+/C0). E-cad- ILC had a poorer prognosis. The identification of patients with ILC of expected poor prognosis may have implications when determining adjuvant therapy. If the prognostic utility of E-cad for ILC is confirmed in future studies and robust guidelines for interpretation of E-cad IHC are developed,14,15 this could extend the use of a well-known marker for the benefit of a substantial proportion of breast cancer patients.

The loss of E-cad expression is shown to promote invasion and metastasis of epithelial cancers, including breast cancer.24 E-cad may be involved in other cellular processes of importance as a tumour suppressor gene.25 Cell-to-cell adhesion involves cytoplasmic catenins and the actin cytoskeleton in addition to

### Table 5. Risk of death from invasive lobular grade 2 compared to invasive ductal carcinoma grade 2

| Tumour characteristics | Number of cases | Deaths from breast cancer | Unadjusted | Adjusted for age | Adjusted for stage | Adjusted for time period of diagnosis (10-year intervals) |
|------------------------|-----------------|---------------------------|------------|-----------------|-------------------|--------------------------------------------------------|
| **ER+**                |                 |                           |            |                 |                   |                                                        |
| Ductal                 | 297             | 100                       | 1.00       | 1.00            | 1.00              | 1.00                                                   |
| Lobular                | 88              | 37                        | 1.71       | 1.17–2.50       | 1.68              | 1.14–2.47                                              |
|                        |                 |                           |            |                 |                   |                                                        |
| **Ki67low**            |                 |                           |            |                 |                   |                                                        |
| Ductal                 | 224             | 71                        | 1.00       | 1.00            | 1.00              | 1.00                                                   |
| Lobular                | 70              | 30                        | 2.01       | 1.31–3.01       | 1.95              | 1.26–3.03                                              |
|                        |                 |                           |            |                 |                   |                                                        |
| **HER2–**              |                 |                           |            |                 |                   |                                                        |
| Ductal                 | 287             | 97                        | 1.00       | 1.00            | 1.00              | 1.00                                                   |
| Lobular                | 93              | 39                        | 1.76       | 1.21–2.56       | 1.74              | 1.19–2.55                                              |
|                        |                 |                           |            |                 |                   |                                                        |
| **ER+, Ki67low and HER2–** |             |                           |            |                 |                   |                                                        |
| Ductal                 | 201             | 61                        | 1.00       | 1.00            | 1.00              | 1.00                                                   |
| Lobular                | 56              | 24                        | 2.16       | 1.34–3.49       | 2.04              | 1.25–3.34                                              |

HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2.

Figure 3. Breast cancer specific survival for invasive lobular and ductal carcinoma grade 2 according to luminal A and luminal B [human epidermal growth factor receptor 2 (HER2)] subtypes. *P*-value from log-rank test of differences in breast cancer specific survival (BCSS) was 0.02.
E-cad, and these mechanisms are complex. Loss of tumour suppressor function and impaired cell-to-cell adhesion, both of which are dependent in part on E-cad, underline the importance of this molecule in breast cancer.

The proportion of E-cad+ ILC reported varies from 0 to 20%. In this study, where histopathological typing was based on morphology only, 23.3% were E-cad+. No cases were revised according to histopathological type in light of E-cad status. Mixed lobular and ductal carcinomas are not infrequent. In this study, mixed tumours were classified as ductal.

Molecular subtyping is based mainly on studies of IDC. IDC is the most common histopathological type, although type is rarely mentioned. For other types, the prognostic value of molecular subtyping remains uncertain. In this study, there were too few ILCs in the non-luminal and HER2 subtypes for reliable results. However, the differences in BCSS in the HER2+ luminal subtypes between ILC and IDC are comparable to the results of the biomarker analyses. Considered together, the results confirm that histopathological type has an independent impact in the prognostication of ILC.

The main strength of this study is the historical nature of the patient cohort enabling complete long-term follow-up. The vast majority of women in this study developed breast cancer in an era prior to the use of hormonal contraception, menopausal hormonal therapy (MHT) and mammography screening, and did not qualify for new therapies as they were introduced, thus enabling insight into the near-natural course of this disease. A drawback is the relative high age of the women, and should be considered when interpreting the results. Others have shown better, similar or poorer prognosis for ILC compared to IDC. Differences in patient populations, follow-up and adjuvant therapy may explain these inconsistencies. Some studies have shown an increased risk of ILC when using MHT. It is unclear whether or not there are differences in prognosis between MHT-associated ILC and ILC in non-users. The majority of cancers in the present study were diagnosed in a time-period or at an age when MHT was rarely used.

In this study, 99 of 116 ILCs were histopathological grade 2. The numbers of grades 1 and 3 were low, and this can be attributed to the morphological features of ILC. This impairs grading as a prognostic

### Table 6. Risk of death from invasive lobular carcinoma grade 2 and invasive ductal carcinoma grade 2 according to luminal A and luminal B (HER2+) subtypes

|                | Number of cases | Deaths from breast cancer | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
|----------------|-----------------|---------------------------|-------------|-------------|-------------|-------------|
|                | Unadjusted      | Adjusted for age          | Adjusted for stage | Adjusted for time-period of diagnosis (10-year intervals) |
| Ductal luminal A | 203             | 62                        | 1.00        | 1.00        | 1.00        | 1.00        |
| Ductal luminal B (HER2+) | 74             | 29                        | 1.48 (0.95–2.31) | 1.55 (0.99–2.42) | 1.70 (1.09–2.67) | 1.36 (0.87–2.12) |
| Lobular luminal A | 56              | 24                        | 2.11 (1.31–3.39) | 2.08 (1.28–3.38) | 2.53 (1.55–4.12) | 2.21 (1.36–3.57) |
| Lobular luminal B (HER2+) | 26              | 10                        | 1.78 (0.91–3.48) | 1.81 (0.92–3.57) | 2.10 (1.07–4.14) | 1.74 (0.88–3.41) |
| **Total**     | **359**         | **125**                   |             |             |             |             |

HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2.

**Figure 4.** Breast cancer specific survival for invasive lobular and ductal carcinoma grade 2 according to E-cadherin status. P-value from log-rank test of differences in breast cancer specific survival (BCSS) was 0.005.

© 2014 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 66, 409–419.
Similarly, the prognostic value of HER2 in ILC may be limited due to the low number of ILCs expressing HER2. However, grade 2 ILC had a consistently poorer prognosis when compared to grade 2 IDC, and the differences were also apparent when the analyses included only tumours with presumed favourable biomarkers. Due to the low number of lobular tumours in our study, we did not have sufficient statistical power to investigate the prognostic value of an unfavourable biomarker profile within lobular cancers. The present study supports the claim that lobular lesions are a distinct family of neoplastic lesions in the breast. The role of E-cad in ILC may not only be in the determination of histopathological type; it may also be more useful than grade in prognostication and in the determination of treatment.

### Acknowledgements

This study has received financial support from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, the Research Council of Norway and the Cancer Fund, St Olav’s Hospital, Trondheim University Hospital, Norway.
The authors thank the Department of Pathology and Medical Genetics. St Olav’s Hospital for making the archives available for the study, the Cancer Registry of Norway for providing the patient data and senior biomedical scientist Borgny Ytterhus for her invaluable work in the laboratory.

Conflicts of interest

The authors declare that they have no competing interests.

References

1. Rakha EA, El-Sayed ME, Powe DG et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur. J. Cancer 2008; 44: 73–83.
2. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004; 6: R149–R156.
3. Lakhani SR, Ellis I, Schnitt SJ, Tan PH, Van de Vijver M, World Health Organization (eds). WHO classification of tumours of the breast. Lyon: International Agency for Research on Cancer (IARC), 2012.
4. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 1957; 11: 359–177.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–410.
6. Rakha EA, Reis-Filho JS, Baehner F et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12: 207.
7. Rakha EA, El-Sayed ME, Lee AH et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J. Clin. Oncol. 2008; 26: 3153–3158.
8. Wachtel MS, Halldorsson A, Dissanaike S. Nottingham grades of lobular carcinoma lack the prognostic implications they bear for ductal carcinoma. J. Surg. Res. 2010; 166: 19–27.
9. Bane AL, Tjan S, Parkes RK, Andrusi I, O’Malley FP. Invasive lobular carcinoma: To grade or not to grade. Mod. Pathol. 2005; 18: 621–628.
10. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann. Oncol. 2013; 24: 2206–2223.
11. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of e-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J. Clin. Pathol. 2008; 61: 615–620.
12. Dabbs DJ, Schnitt SJ, Geyer FC et al. Lobular neoplasia of the breast revisited with emphasis on the role of e-cadherin immuno-histochemistry. Am. J. Surg. Pathol. 2013; 37: e1–e11.
13. Oliveira TM, Elias J Jr, Melo AF et al. Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods. Insights Imaging 2014; 5: 183–194.
14. Brzozowska A, Sodolski T, Duma D, Mazurkiewicz T, Mazur- kiewicz M. Evaluation of prognostic parameters of e-cadherin status in breast cancer treatment. Ann. Agric. Environ. Med. 2012; 19: 541–546.
15. Younis LK, El Sakka H, Haque I. The prognostic value of e-cadherin expression in breast cancer. Int. J. Health Sci. (Qassim) 2007; 1: 43–51.
16. Saadatmand S, de Krijff EM, Sajet A et al. Expression of cell adhesion molecules and prognosis in breast cancer. Br. J. Surg. 2013; 100: 252–260.
17. Engstrom MJ, Opdahl S, Hagen AI et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res. Treat. 2013; 140: 461–473.
18. Kvéale G, Heuch I, Eide G. A prospective study of reproductive factors and breast cancer. Am. J. Epidemiol. 1987; 126: 831–841.
19. Robbins P, Pinder S, de Klerk N et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum. Pathol. 1995; 26: 873–879.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (remark). Breast Cancer Res. Treat. 2006; 100: 229–235.
21. Sinha PS, Bendall S, Bates T. Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers? Eur. J. Surg. Oncol. 2000; 26: 733–737.
22. Talman ML, Jensen MB, Rank F. Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. Acta Oncol. 2007; 46: 801–809.
23. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res. Treat. 2008; 111: 121–127.
24. Gould Rothberg BE, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2006; 100: 139–148.
25. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005; 46: 685–693.
26. Morrogh M, Andrade VP, Giri D et al. Cadherin–catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res. Treat. 2012; 132: 641–652.
27. Kuroda H, Tamaru J, Takeuchi J et al. Expression of e-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Arch. 2006; 448: 500–505.
28. Szasz AM, Nemeth Z, Győrfy B et al. Identification of a claudin-4 and e-cadherin score to predict prognosis in breast cancer. Cancer Sci. 2011; 102: 2248–2254.
29. Rakha EA, Patel A, Powe DG et al. Clinical and biological significance of e-cadherin protein expression in invasive lobular carcinoma of the breast. Am. J. Surg. Pathol. 2010; 34: 1472–1479.
30. Wheeler DT, Tai LH, Brattthauer GL, Waldnner DL, Tavassoli FA. Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am. J. Surg. Pathol. 2004; 28: 1587–1593.
31. Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the e-cadherin/catelin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod. Pathol. 2007; 20: 130–138.
Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008; 216: 141–150.

van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002; 347: 1999–2009.

Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom. 2006; 7: 96.

Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671–679.

Toikkanen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br. J. Cancer 1997; 76: 1234–1240.

Li CI. Risk of mortality by histologic type of breast cancer in the united states. Horm. Cancer 2010; 1: 156–165.

Pestalozzi BC, Zahrieh D, Mallon E et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J. Clin. Oncol. 2008; 26: 3006–3014.

Colleoni M, Rotmensz N, Maisonneuve P et al. Outcome of special types of luminal breast cancer. Ann. Oncol. 2012; 23: 1428–1436.

Hein R, Flesch-Janys D, Dahmen N et al. A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. Breast Cancer Res. Treat. 2013; 138: 529–542.

Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006; 7: 910–918.

Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, Malone KE. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55–74 years of age. Breast Cancer Res. Treat. 2014; 145: 481–489.

Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J. Natl Cancer Inst. 2012; 104: 517–527.